-
Czech duo Muchova and Mensik win US Open mixed doubles title
-
Once a top export, prized Kashmir carpet fades
-
Japan's 'polka dot queen' artist Yayoi Kusama dies aged 97
-
Search for 1,000 missing after deadly Nepal-Tibet floods
-
Nepal-Tibet disaster: what we know
-
Park So-yeon first woman to play for eSports powerhouse South Korea
-
China deploys record number of ships around Taiwan as pressure grows
-
Yayoi Kusama: Japan's kaleidoscopic, troubled 'polka dot queen'
-
Ruthless Bayern target treble as rivals reboot on Bundesliga return
-
Euro champ Hunt 'on her toes' against world's best in Zurich 100m
-
What experts know so far about Nepal's deadly floods
-
Asian chip firms lifted by Nvidia forecast but broader markets struggle
-
UEFA set to withdraw FIFA boycott threat ahead of Champions League draw
-
Search for missing after Nepal-Tibet floods kill 165
-
Sumo moves to beat Japan summer heat as temperatures rise
-
Qantas says profits slump as fuel costs surge
-
'Be more honest': Markets crave clarity from cryptic Fed chair
-
Lofty bond yields, Bessent's intervention pose challenge to Fed's Warsh
-
Climate change leaves its mark on America's largest reservoir
-
The foreigners missing in Nepal's flash floods
-
CIA director warned Russia not to attack NATO members: US media
-
Bond yields are surging: Here's why that could spell trouble
-
Search for missing after Nepal-Tibet floods kills at least 160
-
Fed's Cook rejects Trump mortgage fraud claims
-
Meta, US states agree $18 bn settlement in landmark teen safety case
-
Police probe 'assault allegations' after Carse's nightclub incident
-
What scientists know so far about Nepal's deadly floods
-
How we might hear new Dolly Parton music in the future
-
US general visits Colombia to discuss war on drugs
-
Nvidia doubles revenue, forecasts even more AI spending
-
Meta settlement puts social media industry on notice: 'There will be more'
-
Canada renews push to boycott US products
-
NFL owners approve record Seahawks sale
-
Savio scores on debut as Spurs set-up League Cup tie with Liverpool
-
Nigerian armed groups net nearly $6 mn in ransoms: study
-
Brazil sues Discord over child safety measures, demands $100 mln in damages
-
Savio scores on debut as Spurs advance in League Cup
-
Alberta NDP Urges Smith to Postpone Separation Vote Amid Trade War
-
Mbappe hits treble as Real Madrid thrash Real Sociedad
-
Fenerbahce stun Lyon in Champions League as AEK crush Levski
-
At Dollywood, superfans honor the late singer and local hero
-
Why Global Finance Still Relies on Wall Street Despite Diversification Trends
-
Stocks mixed as oil drops, US inflation stays high
-
Bethlehem Father Seeks Aid for Special Needs Children Amid Health Crisis
-
Bolivia's Paz appoints new economy minister amid bailout talks
-
LIV Golf to lay off majority of staff
-
US designates UK-based Palestine Action as foreign 'terrorist group'
-
How narwhal 'scientists' track Arctic warming
-
'Rocky Horror Picture Show' star Tim Curry dead at 80
-
Iran says US sanctions will achieve nothing
Duly Surgeon First in Illinois to Use Tumor-Illuminating Technology for Ovarian Cancer Surgery
DOWNERS GROVE, IL / ACCESS Newswire / February 25, 2026 / Duly Health and Care this month announced that Dr. Sameer Sharma, a gynecologic oncologist at Duly Health and Care's Chicagoland medical group, DuPage Medical Group, Ltd., is the first physician in Illinois to perform ovarian cancer surgery using Cytalux, a newly approved imaging agent that causes cancerous tissue to "glow" - and can thus help surgeons see and remove tumors with greater precision.
"Ovarian cancer surgery often comes down to what you can't see," Dr. Sharma said. "Cytalux gives us another set of eyes in the operating room. When cancer cells light up, it helps us be more precise, more confident, and ultimately more effective for our patients."
Dr. Sharma brings more than 20 years of experience in gynecologic oncology and performs about 60 advanced ovarian cancer surgeries each year, placing him among the highest-volume ovarian cancer surgeons in the country. Research shows that patients treated by experienced, high-volume surgeons have better outcomes - particularly for ovarian cancer, where complete tumor removal is critical.
Administered prior to surgery, Cytalux causes ovarian cancer cells to "glow" under a specialized camera. That enables surgeons to detect disease that may not be visible to the naked eye.
"For patients, this technology can mean the difference between leaving microscopic disease behind and removing everything we possibly can," Dr. Sharma said. "That matters - not just for today's surgery but for what comes next in their treatment and recovery."
Only a small number of specialized health systems nationwide offer Cytalux for ovarian cancer surgery, placing Duly among a select group delivering cutting-edge cancer care.
"Ovarian cancer remains one of the most deadly gynecologic cancers, claiming more than 12,000 lives each year in the United States - including nearly 500 in Illinois," said Dr. Sharma. "Innovations like this, combined with experienced oncologic surgical care, give us new ways to push outcomes in the right direction - right here in the community."
DuPage Medical Group, Ltd. dba Duly Health and Care of Northern Illinois ("Duly") is Duly's Chicagoland medical group.
About Duly Health and Care
The Duly Health and Care brand consists of some of the largest independent, multi-specialty, physician-directed medical groups in the nation, with more than 1,000 primary care and specialty care providers and over 6,000 team members across more than 150 locations. The Duly Health and Care brand includes three medical groups - DuPage Medical Group Ltd., Quincy Medical Group, and The South Bend Clinic LLC. Duly is deeply committed to caring for patients in traditional and value-based care arrangements, ensuring a focus on quality, efficiency, and enhanced patient experiences throughout the Midwest.
For more information, visit dulyhealthandcare.com
Media Contact
Katelyn Moon
[email protected]
202-982-2444
SOURCE: Duly Health and Care
View the original press release on ACCESS Newswire
F.Ramirez--AT